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The -adrenergic system is involved in the control of energy
metabolism and expenditure. The 2-adrenergic receptor (2-
AR) gene shows polymorphisms that have been associated
with obesity in several studies. In vitro and in vivo studies
suggestdifferences in2-AR-mediated functionbetween these
polymorphisms. The aim of this study was to investigate the
influence of genetic variation in codon 16 of the 2-AR gene on
energy metabolism in humans.
Thirty-four subjects were recruited [Gly16Gly (n  13),
Gly16Arg (n  16), or Arg16Arg (n  5)]. The 2-AR was stim-
ulated with two doses of salbutamol (50 and 100 ng/kg fat-free
mass per minute) after blockade of the 1-adrenergic recep-
tors with atenolol. Energy expenditure and plasma substrate
and hormone concentrations were measured.
The increase in energy expenditure (EE)was significantly
different among groups in which the Arg16Arg group showed
the lowest increase (P < 0.05 vs. Gly carriers). In a multiple
regression model, variations in the increase in nonesterified
fatty acid concentration during salbutamol infusion (partial
r  0.51) and the polymorphism contributed significantly to
the variation in EE. Thirty-five percent of the variation in
EE was explained by these two factors.
We conclude that subjects with the Arg16Arg polymor-
phismof the2-ARgenehave a reduced thermogenic response
to 2-adrenergic stimulation. Although this relatively small
study needs confirmation, the findings support a role for this
polymorphism in the development and maintenance of over-
weight and obesity. (J Clin Endocrinol Metab 90: 2301–2307,
2005)
IT IS WELL DOCUMENTED that both environmental andgenetic factors are involved in the onset and progression
of obesity in humans. Severe obesity appears to have a par-
ticularly strong genetic component and is polygenic in nature
(1). An increasing number of polymorphisms is assumed to
be associated with obesity and has been described in liter-
ature (1). Despite intense effort, the pathways underlying
these associationswith obesity remain elusive. This is largely
due to the complexities circumventing the process of devel-
oping obesity, which include age of onset; polygenic inher-
itance; genetic heterogeneity; incomplete penetrance; un-
known mode of action of disease alleles; effect of ethnicity,
age, gender, and the interaction with environmental factors,
such as diet, physical activity, or smoking status.
Of all contributing factors, the components of the sympa-
thetic nervous system are of interest because this system, in
particular its -adrenergic component, is involved in the
control of energy metabolism and expenditure (2, 3).
One of the receptor subtypes of the -adrenergic system is
the 2-adrenergic receptor (2-AR). It is coupled to a stim-
ulatory G protein that promotes cAMP production, activat-
ing protein kinase A, which mediates a variety of responses,
depending on the cell type. For instance, the lipolytic and gly-
cogenolytic effects of catecholamines are mediated through
members of the 2-AR family (2, 4). One study found that the
2-mediated thermogenic and lipolytic responses are
blunted in obese, comparedwith lean (5). In addition, several
studies (6–13) have shown an association between 2-AR
polymorphisms and weight gain, obesity, or obesity-related
phenotypes. Nine polymorphisms have been identified in
the coding region of the human 2-AR, three of which are
nonsynonymous (14). The two most common variants are
located at codon 16 (Arg16Gly) and codon 27 (Gln27Glu) and
have been studied most in relation to obesity. Both poly-
morphisms result in variations at the amino-terminal site of
the receptor.
In vitro studies have shown differences in agonist-
promoted down-regulation (15) but no differences in agonist
binding or agonist-stimulated adenylyl cyclase activities
among these polymorphisms of the 2-AR gene (16). Func-
tional consequences of these polymorphisms with respect to
adipocyte lipolysis have been reported (17, 18), which may
play a role in obesity. So far, the role of the 2-AR polymor-
phisms in human energy expenditure (EE) has not been
studied.
We investigatedwhether the polymorphism at codon 16 of
the 2-AR gene is of functional importance in human energy
metabolism by direct stimulation of this receptor with a
2-AR agonist in an experimental setting.
Subjects and Methods
Subjects
Thirty-four healthy, normal-weight to moderately obese volunteers
[body mass index (BMI) range 19.1–37.1 kg/m2] participated in this
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study (32men and twowomen, aged 45 0.8 yr, BMI 27.8 0.8 kg/m2).
In part (n 14) theywere recruited from an existing cohort that has been
described previously (13), in which the polymorphisms in the 2-AR
were known; in part they were newly recruited by advertisement (n 
20). The subjects did not use medication. Physical characteristics of the
subjects are summarized in Table 1.
Experimental design
One week before the experimental day, subjects came to the labora-
tory after an overnight fast, and body composition was determined by
hydrostatic weighing with simultaneous lung volume measurements
(Volugraph 2000, Mijnhardt, Bunnik, The Netherlands). Body compo-
sition was calculated according to the equation of Siri (19).
Subjects were asked to refrain from strenuous exercise during 24 h
before the experiment. After an overnight fast, subjects arrived at the
laboratory by bus or car to minimize activity before the measurements.
On arrival, a cannula was inserted into a forearm vein of each arm. One
cannula was used for the infusion of drugs and the other cannula for the
sampling of blood. Next, indirect calorimetry measurements were
started with a ventilated hood system with the subject in recumbent
position and continued for the remainder of the experiment.
The study consisted of three study periods of 45 min. Before the first
period, subjects received a priming dose of 50g/kg fat-freemass (FFM)
atenolol (1-adrenergic receptor antagonist) (Tenormin, Zeneca, Rid-
derkerk, The Netherlands) in 5 min, after which a continuous infusion
of 1.2 g/kg FFM per minute atenolol was started for the remainder of
the experiment. After 45 min atenolol infusion, subjects additionally
received consecutive infusions of 50 and 100 ng/kg FFM per minute
salbutamol (Ventolin, GlaxoWellcome, Zeist, The Netherlands). Each
infusion period lasted 45 min. After 30 and 45 min of each study period,
a blood sample was taken.
Measurements
Whole-body EE and respiratory exchange ratio (RER)weremeasured
by indirect calorimetry, using an open-circuit ventilated hood system. In
the study a homemade system, which is based on the analysis system
for respiration chambers, which has been described previously (20), was
used. The volume of air drawn through the hood was measured by a
dry-gas meter (Schlumberger, Dordrecht, The Netherlands), and the
composition of the in- and outflowing air was analyzed by a paramag-
netic O2 analyzer (Servomex, Crowborough, UK) and an infrared CO2
analyzer (Hartmann and Braun, Frankfurt, Germany). The airflow rate
and the O2 and CO2 concentrations of the in- and outflowing air were
used to compute O2 consumption and CO2 production online through
an automatic acquisition system connected to a personal computer. EE
was calculated according to the formula proposed by Weir (21). EE and
RER values were averaged over the last 15 min of each period. The
reproducibility of the measurement was within 5% as described before
(22).
Total carbohydrate and fat oxidation were calculated using stoichi-
ometric equations (23):
Total fat oxidation (grams per minute)  1.695 VO2 (liters per
minute)  1.701 VCO2 (liters per minute).
Total carbohydrate oxidation (grams perminute) 4.585VCO2 (liters
per minute)  3.226 VO2 (liters per minute).
Substrate oxidation was expressed as percentage of the contribution
to total EE (1 g fat  37.8 kJ and 1 g carbohydrate  16.9 kJ).
Heart rate was monitored by conventional electrocardiography.
Blood pressure was measured three times by an automated blood pres-
sure device (OMRON 705CP, Hamburg, Germany) during the last 5 min
of each study period. Themeans of these threemeasurements were used
for further analysis.
Analytical methods
Genomic DNA of the subjects was extracted from leukocytes by
digestion with proteinase K followed by phenol/chloroform extraction.
Determination of the polymorphism was performed using a PCR-
restriction fragment length polymorphism analysis as described before
(18).
Blood samples for the determination of nonesterified fatty acids (NE-
FAs), glycerol, glucose, and insulin were preserved with sodium-EDTA
and those for norepinephrine and epinephrine with heparin plus glu-
tathione (1.5%wt/vol). Blood sampleswere immediately centrifuged for
10 min at 800  g at 4 C. Plasma was rapidly frozen in liquid nitrogen
and stored at 70 C until further analysis. Plasma NEFA concentration
was measured with the NEFA C kit (99475409, Wako, Neuss, Germany),
plasma glycerol concentrationwasmeasuredwith a glycerol kit (148270,
Boehringer, Mannheim, Germany), and plasma glucose concentration
was measured with a glucose kit (UniKit III, 07367204, Roche, Basel,
Switzerland), all on a Cobas Fara centrifugal analyzer (Roche Diagnos-
tica, Basel, Switzerland). Plasma insulin level was determined with a
double-antibody RIA (Insulin RIA 100, Pharmacia, Uppsala, Sweden).
The homeostasis model assessment (HOMA) index was calculated ac-
cording to Matthews et al. (24) using baseline plasma glucose and base-
line plasma insulin levels. Plasma norepinephrine and epinephrine lev-
els were determined by HPLCwith electrochemical detection according
to the method of Alberts et al. (25) using a ClinPrep kit (Recipe, Munich,
Germany).
Data analysis
All data are presented as mean sem. Data for EE were adjusted for
FFM for group comparison (26). The change () in EE induced by the
highest dose of salbutamol (100 ng/kg FFM per minute) was calculated
by subtracting baseline EE from the EE at 100 ng/kg FFM per minute
salbutamol. Changes in the other variables were calculated the same
way.
One-way ANOVAwith repeated measurements was used to analyze
the effects of salbutamol administration in the total group of subjects and
the three polymorphism groups. Differences among the codon 16 poly-
morphism groups at baseline and in response to salbutamol adminis-
tration were analyzed by one-way ANOVA. Post hoc pairwise compar-
isons were made using Bonferroni correction.
Simple regression analysiswas performedwithEE as the dependent
variable and different parameters as independent variables (see Table 3).
Multiple regression analysis was conducted to estimate the independent
contributions of the variables associated with EE. All variables that
were correlated with EE in the simple regression analysis with a P 
0.20 were included in the analysis. In addition, the polymorphism
groups were entered as dummy variables into the multiple regression
model. P  0.05 was considered to be statistically significant.
Results
Responses to salbutamol infusion in the whole group
Table 2 shows changes in all parameters studied at base-
line and during administration of increasing doses of salbu-
tamol for the whole group of subjects. EE, heart rate, plasma
norepinephrine, and NEFA and glycerol concentrations
TABLE 1. Subject characteristics of groups with different
polymorphisms at codon 16 of the 2-adrenergic receptor gene
(mean  SEM)
Gly16Gly
(n  13)
Gly16Arg
(n  16)
Arg16Arg
(n  5)
Gender (M/F) 12/1 16/0 4/1
Weight (kg) 83.6  4.3 87.0  3.5 86.5  12.9
Height (m) 1.73  0.03 1.78  0.02 1.74  0.05
Age (yr) 46.9  1.4 45.5  1.3 41.5  1.1
Fat percentage (%) 28.0  2.6 27.4  1.8 35.0  1.1
Fat mass (kg) 23.9  2.7 24.6  2.4 30.7  5.1
FFM (kg) 59.6  3.0 62.4  1.7 55.9  7.8
BMI (kg/m2) 27.8  1.2 27.7  1.3 28.1  3.0
HOMA index 2.25  0.52 2.15  0.33 4.90  1.84a,b
a Significantly different between Arg16Arg and Gly16Arg (P 
0.05).
b Tendency for difference between Arg16Arg and Gly16Gly (P 
0.06).
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showed statistically significant increases (at least P  0.05).
Plasma epinephrine concentrations were significantly low-
ered during salbutamol infusion (P  0.01). No statistically
significant changes in RER, blood pressure (BP), plasma glu-
cose, lactate, and insulin were found.
Baseline values and responses to salbutamol infusion in the
2-AR codon 16 polymorphism groups
Baseline EE adjusted for FFM was similar in all polymor-
phism groups (4.89  0.14, 4.89  0.06, and 4.92  0.23
kJ/min for Gly16Gly, Gly16Arg, and Arg16Arg, respec-
tively, NS). There was a significant difference in the increase
in EE (EE) among groups (ANOVA, P  0.05) (Fig. 1). Post
hoc analysis showed that the response was significantly dif-
ferent between the Arg16Arg and the Gly16Arg groups (P
0.05) and between Arg16Arg and Gly carriers (P  0.05).
At baseline RER did not differ among groups, nor did
RER (P  0.41) (Fig. 2). Fat oxidation at baseline was not
significantly different among groups (54.4  3.4, 55.7  3.2,
and 44.6  6.3% of total EE for Gly16Gly, Gly16Arg, and
Arg16Arg, respectively, P  0.25) nor was carbohydrate ox-
idation (47.0 3.9, 45.6 3.9, and 57.9 7.0% of total EE for
Gly16Gly, Gly16Arg, and Arg16Arg, respectively, P 0.25).
There was no difference in change of fat and carbohydrate
oxidation (as percentage of total EE) in response to salbuta-
mol among groups (ANOVA, both P  0.43).
Plasma concentrations of NEFAs, glycerol, glucose, insu-
lin, epinephrine, and norepinephrine did not differ signifi-
cantly among groups at baseline nor during salbutamol in-
fusion. The HOMA index, however, was significantly
different among groups (ANOVA, P  0.05), in which the
Arg16Arg group showed the highest HOMA index.
During salbutamol infusion, plasma NEFA levels (Fig. 3)
and norepinephrine levels (Fig. 4) increased significantly in
all polymorphism groups (P  0.05), with no significant
difference among groups. Plasma concentrations of glycerol,
glucose, insulin, and epinephrine changed significantly in
the Gly16Gly and Gly16Arg groups (P 0.01) but not in the
Arg16Arg group; however, the responses to salbutamol in-
fusion did not differ among groups. Plasma lactate levels
were significantly higher at baseline and during salbutamol
in the Arg16Arg group, compared with the Gly carriers
(ANOVA, P  0.05), but the lactate response to salbutamol
infusion did not differ among groups (Fig. 3).
TABLE 2. Metabolic parameters at different doses of salbutamol for the whole group (n  34)
Salbutamol (ng/kg FFM  min) 0 50 100 P value (ANOVA)
Energy expenditure (kJ/min) 4.8  0.1 5.1  0.1 5.3  0.1 0.037
RER 0.83  0.01 0.85  0.01 0.82  0.01 0.183
Fat oxidation (% of total energy expenditure) 53.5  2.2 48.5  2.8 55.6  3.2 0.179
Carbohydrate oxidation (% of total energy expenditure) 47.9  2.8 53.6  3.2 45.7  3.5 0.181
Heart rate (beats/min) 55.9  1.2 62.8  1.2 71.2  1.4 0.001
Diastolic blood pressure (mm Hg) 83.9  1.8 81.7  1.7 78.2  1.7 0.075
Systolic blood pressure (mm Hg) 118.1  2.0 118.9  1.9 121.1  1.9 0.532
[Norepinephrine] (ng/liter) 456.0  20.6 513.3  33.2 579  32.7 0.014
[Epinephrine] (ng/liter) 33.9  3.5 24.1  2.5 21.8  2.1 0.006
[NEFA] (mol/liter) 366.6  21.1 580.2  30.8 724.9  42.1 0.001
[Glycerol] (mol/liter) 58.5  3.7 84.3  5.2 106.8  7.2 0.001
[Glucose] (mmol/liter) 5.40  0.12 5.36  0.10 5.49  0.10 0.656
[Lactate] (mmol/liter) 0.97  0.06 1.00  0.05 1.15  0.05 0.055
[Insulin] (mU/liter) 10.1  1.3 13.5  1.8 15.2  1.6 0.075
Data represent mean  SEM.
FIG. 1. EE adjusted for FFM for the codon 16 polymor-
phisms in the 2-AR at baseline and during infusion of
salbutamol. *, P  0.05 vs. baseline; #, P  0.05
Arg16Arg vs. Gly carriers.
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Baseline values for heart rate and systolic and diastolic BP
were not significantly different among polymorphism
groups. Systolic BP increased in the Gly16Gly and Arg16Arg
groups (P  0.05) but not in the Gly16Arg group (P  0.54).
Diastolic BP significantly decreased in the Gly16Gly and
Gly16Arg groups (P  0.05), but the decrease did not reach
statistical significance in the Arg16Arg group (P  0.08).
However, the changes in heart rate and systolic and diastolic
BP during salbutamol infusion did not differ significantly
among groups (data not shown).
Factors contributing to the EE response to
salbutamol infusion
Simple regression analysis with EE as the dependent
variable showed statistically significant correlations with
basal NEFA and insulin concentration, NEFA, glycerol,
HOMA index, and RER (Table 3). Multiple stepwise re-
gression analysis with EE as the dependent variable and
basal plasma NEFA and insulin concentration, NEFA,
HOMA index, RER, age, and codon 16 polymorphism as
independent variables was performed subsequently. Be-
cause glycerol and NEFAs are both parameters of lipolysis
and are highly correlated (R2 0.838), only basal NEFAs and
NEFAs and not basal glycerol and glycerol were used in
the multiple regression analysis. The analysis indicated sta-
tistically significant associations of NEFAs and the codon
16 polymorphism with EE. No significant association with
the other variables was found. The partial correlation coef-
ficient for NEFAs was 0.51. The polymorphism added an-
other 10% to the explained variance inEE. Thewholemodel
therefore explained 35% of the variation in EE (adjusted R2
 0.354, P  0.001). Introducing basal and glycerol instead
of basal and NEFAs into the model gave similar results,
NEFAs being replaced by glycerol.
Discussion
The aim of the present study was to examine the influence
of polymorphisms in codon 16 of the 2-AR gene on EE and
substrate oxidation during2-AR stimulation by infusing the
2-AR agonist salbutamol. During salbutamol infusion sub-
jects with the Arg16Arg variant of the 2-AR gene showed
a blunted increase in EE, and their plasma lactate levels were
higher. Fat oxidation as percentage of total EE and plasma
NEFA and glycerol levels did not differ among groups, nor
was there a difference in response to salbutamol. Multiple
regression analysis showed that the polymorphism in codon
16 of the 2-AR gene and plasma NEFA or glycerol change
but not RER change, percent body fat, BMI, age, and HOMA
index were significantly associated with the change in EE.
The combined infusion of salbutamol and atenolol selec-
tively stimulates the 2-AR, as shown previously (27). This
selective stimulation resulted in the expected increases in EE,
heart rate, plasma glycerol, NEFAs, lactate, insulin, and nor-
epinephrine concentrations and in reductions in plasma epi-
nephrine levels and diastolic BP (27, 28). There was no clear
change of RER during salbutamol infusion in this study.
However, changes in RER have been inconsistent in previous
studies (27, 28).
The 2-AR gene contains the genetic code for the receptor
protein. Several variants in this gene have been described in
literature (14). Three of the single-nucleotide polymor-
phisms, at nucleotides 46, 79, and 491, lead to amino acid
substitution at codons 16, 27, and 164 in the coding region of
the gene andmight therefore have consequences for receptor
function (29). When expressed in cells, the receptors with
polymorphisms at codons 16 and 27 have been associated
with differences in cellular 2-AR trafficking (30). The more
rare polymorphism at codon 164 is associated with de-
pressed functional coupling toGs and reduced2-adrenergic
receptor sequestration (31). Large et al. (18) showed that
isolated abdominal sc fat cells from women homozygous for
the Arg16 polymorphism of the 2-AR had a 5-fold lower
sensitivity for 2-AR agonist-induced lipolysis than fat cells
from women heterozygous or homozygous for Gly16, inde-
pendent of percent body fat of the women. More recently it
was shown that fat cells from subjects with different ho-
FIG. 2. RER for the codon 16 polymorphisms in the
2-AR at baseline and during infusion of salbutamol. #,
P  0.05 Arg16Arg vs. Gly carriers.
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mozygous haplotypes of the 2-AR gene differed about 250-
fold in sensitivity to terbutaline-induced lipolysis (17). The
least sensitive homozygous haplotype group in this study
contained the Arg variant at codon 16 (17).
This study extends these findings and demonstrates a re-
duced 2-AR agonist-induced thermogenic response in in-
dividuals homozygous for the Arg16 polymorphism of the
2-AR gene. On the basis of changes in plasma NEFA and
glycerol concentrations, we could not confirm the reduced
lipolytic response to 2-AR stimulation in the Arg16Arg
group, which has been reported by Large et al. (18) based on
in vitro lipolysis. This might be related to the limitations of
plasma NEFA concentration as a measure of lipolysis be-
cause not only lipolysis but also reesterification and NEFA
oxidation affect plasma NEFA concentrations. The higher
RER and plasma lactate concentrations at baseline as well as
during salbutamol infusion in the Arg16Arg group suggest
that their energy production relies more on carbohydrate
oxidation, which would be compatible with a reduced
lipolysis.
This study shows that the codon16 polymorphism has a
significant effect on the salbutamol-induced thermogenic re-
sponse, independent of the change in NEFAs. The explana-
tion for this effect is not directly apparent from our study. It
could be that the 2-AR-stimulated muscle and liver glyco-
gen breakdown is also affected by the polymorphism, thus
resulting in differences in carbohydrate substrate availability
and oxidation (4).
It is not surprising that the study revealed a correlation
between the change in NEFAs and the thermogenic response
because we and others have previously shown an increase in
EE during the infusion of a triglyceride emulsion, which
elevates plasma NEFA levels (28, 32–34), although this is not
found in all studies (35, 36), which may be related to differ-
ences in patient populations and study design. In addition,
part of the increase in EE induced by dobutamine, a 1-
adrenergic agonist, can be blocked by inhibiting lipolysis
with nicotinic acid (37).
Previous studies have suggested that the 2-AR is in-
volved in the reduced-AR-mediated increase in lipolysis (5,
38, 39), lipid oxidation, and thermogenesis (5) in obese com-
pared with lean individuals. This study suggests that vari-
ations in the lipolytic response to 2-adrenergic stimulation
are associated with variations in the thermogenic response.
BMI and fat percentage were negatively correlated with
NEFA in our study (P  0.01 and P  0.06, respectively),
FIG. 3. Plasma NEFA concentration (micromoles per liter), plasma glycerol concentration (micromoles per liter), plasma glucose concentration
(millimoles per liter), and plasma lactate concentration (millimoles per liter) for the codon 16 polymorphisms in the 2-AR at baseline and during
infusion of salbutamol. *, P  0.05 vs. baseline; #, P  0.05 Arg16Arg vs. Gly carriers.
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which supports these earlier findings. Whether the associa-
tion between these variations in 2-AR-mediated NEFA
and the variation in body fat are completely independent of
the codon 16 polymorphism remains to be determined, but
as discussed above, no association between the polymor-
phism and the response of plasma NEFAs or glycerol was
found in this study. Other factors that might have influenced
the lipolytic response are age, insulin sensitivity, 2-adren-
ergic receptor sensitivity and other polymorphisms in the
2-AR gene or other genes associated with lipolysis. Aging
is known to reduce -adrenergic sensitivity (40). The
Arg16Arg group tended to be slightly, although not signif-
icantly (P  0.11), younger than the other two groups. This
difference in age would only tend to reduce the difference in
responsiveness between the polymorphism groups. It is
therefore unlikely that the differences in thermogenic sen-
sitivity among groups are due to age differences. HOMA
index as a measure for insulin sensitivity was different
among polymorphism groups (Table 1) and correlated with
EE but did not significantly contribute to the multiple re-
gressionmodel. As to be expected, theHOMA indexwas also
associated with fat mass.
Subjects carrying the Arg16Arg polymorphism were all
carriers of theGln27Gln polymorphismof the2-AR gene. Of
the Gly16Gly carriers, one subject had the Gln27Gln poly-
morphism and seven had the Gln27Glu polymorphism. Sub-
jectswith theArg16Gly polymorphismwere either Gln27Gln
(n 7) orGln27Glu (n 9). Limiting the analysis to theGln27
homozygotes (n  13) revealed the same difference in ther-
mogenic response between Gly16 carriers (n  8) and
Arg16Arg carriers (n 5) as in the total group. It is therefore
unlikely that the polymorphism at codon 27 was responsible
for the differences in thermogenic response between the
Arg16Arg subjects and the Gly16 carriers.
We conclude that subjects with the Arg16Arg polymor-
phism of the 2-AR have a reduced thermogenic response to
2-adrenergic stimulation. Although this relatively small
study needs confirmation, the findings support a role for this
polymorphism in the development andmaintenance of over-
weight and obesity, as suggested by association studies (12,
17, 18, 41).
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